Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers.

@article{Nakashima1998PharmacokineticsAS,
  title={Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers.},
  author={Mitsuyoshi Nakashima and Mitsutaka Kanamaru and Kazuo Umemura and Kazuhisa Tsuruta},
  journal={Journal of clinical pharmacology},
  year={1998},
  volume={38 1},
  pages={40-4}
}
The safety and pharmacokinetics of a novel recombinant soluble human thrombomodulin, ART-123 were evaluated in single- and multiple-dose studies involving 16 healthy male volunteers. ART-123 was administered by intravenous infusion over 2 hours. The single-dose study indicated that plasma ART-123 levels at doses of 0.03, 0.1, and 0.3 mg declined biexponentially and those half-lives were approximately 4 hours (t1/2 alpha) and 20 hours (t1/2 beta), respectively. The mean plasma peak concentration… CONTINUE READING